Compare Globus Medical Inc. Class A Common Stock (GMED) vs Ventas Inc. Common Stock (VTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Ventas Inc. Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Ventas Inc. Common Stock trades at $85.53 (market cap $43.01B). The key difference: Ventas Inc. Common Stock is far larger — about 4.2× Globus Medical Inc. Class A Common Stock's market cap, and Ventas Inc. Common Stock pays a 2.48% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Ventas Inc. Common Stock for 6 Days on average.
| GMED | VTR | |
|---|---|---|
Market Cap | $10.25B | $43.01B |
Volume | 1,108,124 | 4,035,460 |
Sector | Health | Real Estate |
52-Week High | $96.82 | $100.53 |
52-Week Low | $58.33 | $68.89 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.76B | $55.73B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Ventas (VTR) trades at $83.85, up 0.37% today, amid a bearish technical signal with resistance near $84. The REIT reported Q2 2026 EPS of $0.14, slightly missing expectations, but maintains strong revenue growth with 2026 guidance at $6.4B. Analyst sentiment is positive with a $99.14 consensus target, supported by demographic tailwinds in senior housing.
The outlook for VTR is cautiously optimistic, driven by aging population trends boosting demand for senior housing. Risks include high valuation multiples and negative cash flow from aggressive investing. Wall Street's buy ratings (56%) suggest confidence in long-term growth, but investors should monitor earnings consistency and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Ventas Inc. Common Stock
Ventas is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, medical office buildings, and research-related facilities.
Read more on VTR →
